insights_auto
Kwa nini 4547 imepungua kwa 2.87%?
Fahamu zaidichevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥ 3,720.00
arrow_downward
-2.87%(-110.00) Siku 1
2 Okt, 10:53:17 GMT +9 · JPY
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 4547...
Fungua
JP¥ 3,810
Juu
JP¥ 3,815
Chini
JP¥ 3,715
Mtaji wa soko
173.14B
Wastani wa kiasi cha mauzo
elfu 66.55
Kiasi cha mauzo ya hisa
elfu 22.40
Gawio
3.23%
Mgawo wa faida wa kila robo mwaka
JP¥ 30
Tarehe ya kutojumuisha gawio
29 Sep 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
11.03
Juu kwa wiki 52
JP¥ 5,040
Chini kwa wiki 52
JP¥ 3,500
EPS
JP¥ 337
Hisa za wawekezaji
46.72M
Idadi ya wafanyakazi
elfu 2
Fungua
JP¥ 3,810
Juu
JP¥ 3,815
Chini
JP¥ 3,715
Mtaji wa soko
173.14B
Wastani wa kiasi cha mauzo
elfu 66.55
Kiasi cha mauzo ya hisa
elfu 22.40
Gawio
3.23%
Mgawo wa faida wa kila robo mwaka
JP¥ 30
Tarehe ya kutojumuisha gawio
29 Sep 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
11.03
Juu kwa wiki 52
JP¥ 5,040
Chini kwa wiki 52
JP¥ 3,500
EPS
JP¥ 337
Hisa za wawekezaji
46.72M
Idadi ya wafanyakazi
elfu 2
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
The Lufkin Daily News
·
dakika 55 zilizopita
Australia's Sunrise Energy Metals plans US redomicile, primary Nasdaq listing
MarketBeat
·
dakika 58 zilizopita
Insider Selling: Photronics (NASDAQ:PLAB) Director Sells $307,500.00 in Stock
The Globe and Mail
·
dakika 41 zilizopita
Kaplan Fox Encourages Investors of Fluence Energy, Inc. (NASDAQ: FLNC) to Contact the Firm to Learn About Their Legal Rights
MarketWatch
·
saa 5 zilizopita
The stock market is anything but normal right now — and these charts show it
Wasifu
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Kuhusu Kissei Pharmaceutical Co Ltd
Afisa Mkuu Mtendaji (CEO)Mutsuo Kanzawa
Wafanyakazielfu 1.79
Lilianzishwa9 Ago 1946
Makao makuuMatsumoto, Mkoa wa Nagano, Japani
Sekta-
Tovutikissei.co.jp